PSMA is a well-known target for prostate cancer, using PET isotopes for imaging (68Ga, 18F) and β-emitters (90Y, 177Lu) for therapeutic applications of (metastasised) prostate cancer. Here, FOLH1 is linked to prostate carcinoma.